Saturday 17 October 2026
Export NNVC’s income statement to Excel — free account
NanoViricides, Inc.
NNVC Healthcare Biotechnology
In the quarter to June 2026, EPS grew 24.1% and free cash flow fell 23.9%, each against the same quarter a year earlier.
1.38
0.01
+0.73%
Follow NNVC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
1.06 | 4.43 | 3.17 | 2.66 |
Net Debt/EBITDA |
0.68 | 2.45 | 1.69 | 1.32 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.89 | 0.92 | 0.97 | 0.95 | |
Capex/Depreciation |
(0.63) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.04 | 0.03 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.10) | (0.10) | (0.09) | (0.11) | |
Cash per Share |
0.07 | 0.26 | 0.15 | 0.14 | |
Shareholders Equity per Share |
0.42 | 0.56 | 0.42 | 0.43 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.42 | 0.56 | 0.42 | 0.43 | |
Free Cash Flow |
(1.68) | (2.05) | (1.93) | (2.12) | |
Working Capital |
0.07 | 4.10 | 2.31 | 1.97 | |
Capital Expenditures |
(0.08) | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
0.07 | 4.10 | 2.31 | 1.97 | |
| Other line items | |||||
Quick Ratio |
0.95 | 4.31 | 3.02 | 2.35 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.09) | (0.10) | (0.09) | (0.11) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.25 | 1.13 | 1.10 | 1.22 | |
Average Assets |
10.05 | 11.92 | 10.13 | 9.35 | |
Average Common Equity |
8.64 | 10.73 | 8.99 | 8.10 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 30 Sep 2026